Latest Regulatory Filings News

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

JAYRIDE Group has amended its quarterly cash flow report to correct classification errors, while outlining plans for a new SaaS platform rollout and potential capital raising to support operations.

Kingsgate Consolidated has secured a US$25 million standby loan facility with Nebari, significantly reducing its debt and improving financing terms. This move marks a major step in the company’s de-gearing strategy while maintaining funding flexibility.

Telix Pharmaceuticals reports positive Phase 3 results for its prostate cancer imaging agent Illuccix in China, paving the way for a near-term regulatory submission. Meanwhile, the company advances FDA resubmissions for its glioma and kidney cancer imaging candidates.

Dubber Corporation has secured a significant five-year contract with a leading North American telecommunications provider to deliver Mobile Voice Recording and AI-driven conversation analytics, marking a pivotal expansion in its global footprint.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.

Micro-X has raised $6.18 million through a placement that sees strategic partner Billion Prima increase its stake to 8.6%, funding key commercial and manufacturing scale-up initiatives in medical imaging.

Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.

DataWorks Group signals a turning point with its strongest quarterly operating cash flow since refocusing on its core RegTech business, driven by key contracts in Australia and Ontario.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

White Energy Company Limited has successfully closed a 5 for 12 entitlement offer, raising approximately $3.5 million before costs, with underwriter Morgans Corporate Limited covering the shortfall.